Molecular diagnostics of myeloproliferative neoplasms

Stephen E. Langabeer1, Hajnalka Andrikovics2, Julia Asp3, Beatriz Bellosillo4, Serge Carillo5, Karl Haslam1, Lasse Kjaer6, Eric Lippert7, Olivier Mansier7, Elisabeth Oppliger Leibundgut8, Melanie J. Percy9, Naomi Porret8, Lars Palmqvist3, Jiri Schwarz10, Mary F. McMullin11, Susanne Schnittger12, Niels Pallisgaard13, Sylvie Hermouet14,15 on behalf of the MPN&MPNr-EuroNet

1Cancer Molecular Diagnostics, St. James’s Hospital, Dublin, Ireland; 2Laboratory of Molecular Diagnostics, Hungarian National Blood Transfusion Service, Budapest, Hungary; 3Department of Clinical Chemistry and Transfusion Medicine, Institute of Biomedicine, Sahlgrenska Academy University of Gothenburg, Gothenburg, Sweden; 4Pathology Department, Hospital del Mar, Barcelona, Spain; 5Département de Cytologie Clinique, Centre Hospitalier Universitaire de Nîmes, Nîmes, France; 6Department of Hematology, Roskilde Hospital, Roskilde, Denmark; 7Laboratoire d’Hématologie, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; 8Department of Hematology, University Hospital Bern, Bern, Switzerland; 9Department of Haematology, Belfast City Hospital, Belfast, UK; 10Department of Hematology, Institute of Hematology and Blood Transfusion, Prague, Czech Republic; 11Centre for Cancer Research and Cell Biology, Queen’s University, Belfast, UK; 12MML Munich Leukemia Laboratory, Munich, Germany; 13Department of Clinical Immunology and Biochemistry, Vejle Hospital, Vejle, Denmark; 14Laboratoire d’Hématologie, Centre Hospitalier Universitaire de Nantes, Nantes; 15Inserm UMR89/CNRS UMR6299, Centre de Recherche en Cancérologie Nantes-Angers, Institut de Recherche en Santé de L’Université de Nantes, Nantes, France

Abstract

Since the discovery of the JAK2 V617F mutation in the majority of the myeloproliferative neoplasms (MPN) of polycythemia vera, essential thrombocythemia and primary myelofibrosis ten years ago, further MPN-specific mutational events, notably in JAK2 exon 12, MPL exon 10 and CALR exon 9 have been identified. These discoveries have been rapidly incorporated into evolving molecular diagnostic algorithms. Whilst many of these mutations appear to have prognostic implications, establishing MPN diagnosis is of immediate clinical importance with selection, implementation and the continual evaluation of the appropriate laboratory methodology to achieve this diagnosis similarly vital. The advantages and limitations of these approaches in identifying and quantitating the common MPN-associated mutations are considered herein with particular regard to their clinical utility. The evolution of molecular diagnostic applications and platforms has occurred in parallel with the discovery of MPN-associated mutations, and it therefore appears likely that emerging technologies such as next-generation sequencing and digital PCR will in the future play an increasing role in the molecular diagnosis of MPN.

Key words myeloproliferative neoplasms; polycythemia vera; essential thrombocythemia; primary myelofibrosis; molecular diagnostics; JAK2, MPL, CALR

Correspondence Stephen E. Langabeer, PhD FRCPath, Cancer Molecular Diagnostics, Central Pathology Laboratory, St. James’s Hospital, Dublin 8, Ireland. Tel: +353 1 4103576; Fax: +353 1 4103513; e-mail: slangabeer@stjames.ie

Accepted for publication 30 April 2015 doi:10.1111/ejh.12578

The three diseases of polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF) are related on the basis of their overlapping laboratory and clinical features. They are commonly referred to as the classical Philadelphia chromosome-negative myeloproliferative neoplasms (MPN), and it is the molecular diagnosis of these diseases which will be considered herein. The landmark discovery of the JAK2 V617F (c.1849G>T) ten years ago (1–4) not only revolutionised the area of MPN molecular diagnostics but has also prompted disease re-classification, investigation into many new aspects of MPN genetics and biology, and has led to the clinical introduction of novel therapeutic agents (5, 6). The presence of the JAK2 V617F in most PV patients and in 50–60% of patients with ET and PMF allows this mutation to be utilised as a marker of disease burden with this approach becoming a useful measure of assessing response to various therapeutic interventions. Subsequent identification of further recurring mutations specific to MPN...
subtypes, such as JAK2 exon 12 (7), MPL exon 10 (8), CALR exon 9 (9, 10), and several other MPN-associated mutations (Table 1) allows the design of molecular diagnostic algorithms that are able to identify a clonal marker of disease in the vast majority of patients with a classical MPN. Implementation of such algorithms requires consideration of which patients to screen, which type of methodology to employ, technical aspects of the selected assays such as reliability, reproducibility and analytical sensitivity, how results should be reported, and what options are available for both standardisation and prospective proficiency assessment. This review aims to address the laboratory aspects of MPN molecular diagnosis and their clinical utility.

**JAK2 V617F mutation**

Parallel functional, genetic and genomic approaches lead to the breakthrough identification of the JAK2 V617F mutation in MPN patients (1–4). Subsequent studies confirmed the presence of this mutation in the majority of PV cases, in up to 60% of ET and PMF patients, and at a lower frequency in other myeloid malignancies such as myelodysplastic syndromes (MDS), particularly refractory anaemia with ringed sideroblasts with marked thrombocytosis (RARS-T), and acute myeloid leukaemia (AML) (11, 12). The obvious benefit of molecular diagnostic markers is the demonstration of primary clonal hematopoietic disorders, and its distinction from a reactive myeloproliferation with the importance of JAK2 V617F detection acknowledged by its inclusion as a major diagnostic criterion for PV, ET and PMF in the World Health Organization (WHO) classification (5). The presence of the JAK2 V617F mutation in those cases not fulfilling WHO criteria suggests a latent MPN; such scenarios include splanchnic vein thrombosis or an indolent, subclinical MPN (13, 14).

Pre-analytical variables that should be considered for the detection of the JAK2 V617F, and all other MPN-associated mutations, include the type of sample, cellular fraction of the sample and the nucleic acid template (15). Detection of the JAK2 V617F mutation can be achieved by Sanger sequencing but initial reports immediately demonstrated that this method underestimated the number of patients harbouring the mutation and suggested that an allele-specific PCR (AS-PCR) approach could improve the detection rate (2). Alternative qualitative methods to detect the JAK2 V617F include high-resolution melting (HRM) analysis and denaturing high-performance liquid chromatography that have the advantage of being able to identify the rare, alternative JAK2 exon 14 mutations (16, 17). The limitation of qualitative assays is their inability to identify those patients with lower allele burdens (15), and therefore, quantitative, real-time, allele-specific PCR (AS-qPCR) assays have been widely adopted.

**JAK2 V617F quantitation**

The initial descriptions of the JAK2 V617F mutation in MPN showed that various profiles existed, with some patients showing a complete disappearance of their wild-type allele by Sanger sequencing whilst others had seemingly heterozygous mutations (1). These homozygous profiles could be explained by mitotic recombination (3). Taken together with the low mutational load which could only be detected by a more sensitive AS-PCR technique (2), these data suggested that, even though ‘pure myeloid’, that is selected granulocytes were analysed, the mutational load was distinct from the expected 0%, 50% or 100% for wild type, heterozygous or homozygous patients, respectively. Further studies indicated that the different MPN phenotypes had different mutational loads (18, 19), with more than half of PV and fibrotic PMF patients having greater than 50% JAK2 V617F, whilst most ET and prefibrotic PMF patients had less than 50%. The mutation status of single cells analysed by genotyping colonies clearly demonstrated that PV patients had a mix of homozygous and heterozygous cells, whilst ET patients had nearly exclusively heterozygous cells, explaining that their mutational burden was overall less than 50% (20). However, some PV patients with demonstrable homozygous clones had less than 50% JAK2 V617F mutational load, indicating that the term ‘heterozygous’ sometimes used to refer to these patients is inappropriate. Therefore, a JAK2 V617F burden above 50% indicates that only a proportion of the cells analysed are homozygous for the mutation.

**Table 1** Commonly mutated genes in the myeloproliferative neoplasms

<table>
<thead>
<tr>
<th>Gene</th>
<th>Chromosome location</th>
<th>Mutation location</th>
<th>Frequency (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>JAK2</td>
<td>9p24</td>
<td>exon 14</td>
<td>PV 97, ET 50–60, PMF 55–60</td>
</tr>
<tr>
<td>JAK2</td>
<td>9p24</td>
<td>exon 12</td>
<td>rare 1–2, rare</td>
</tr>
<tr>
<td>MPL</td>
<td>1p34</td>
<td>exon 10</td>
<td>rare 3–5, rare</td>
</tr>
<tr>
<td>CALR</td>
<td>1p32</td>
<td>exon 9, 3q13</td>
<td>rare 20–30, rare</td>
</tr>
<tr>
<td>TET2</td>
<td>4p24</td>
<td>all coding regions</td>
<td>10–20, rare 5–20</td>
</tr>
<tr>
<td>IDH1/IDH2</td>
<td>2q33/15q26</td>
<td>exons 4</td>
<td>rare, rare, rare 5</td>
</tr>
<tr>
<td>DNMT3A</td>
<td>2p23</td>
<td>exons 7–23</td>
<td>5–10, 1–5, 5–10</td>
</tr>
<tr>
<td>ASXL1</td>
<td>2q11</td>
<td>exon 13</td>
<td>2–5, 2–5, 15–30</td>
</tr>
<tr>
<td>EZH2</td>
<td>7q33–7q36</td>
<td>all coding regions</td>
<td>1–3, rare, rare 5–10</td>
</tr>
<tr>
<td>CBL</td>
<td>11q23</td>
<td>exons 8–9</td>
<td>rare, rare, rare 5–10</td>
</tr>
<tr>
<td>SH2B3</td>
<td>12q24</td>
<td>exon 1</td>
<td>rare, rare, rare</td>
</tr>
<tr>
<td>SF3B1</td>
<td>3p22</td>
<td>exons 12–16</td>
<td>rare, rare, rare 5–10</td>
</tr>
<tr>
<td>SRSF2</td>
<td>1q12</td>
<td>exon 1</td>
<td>rare, rare, rare 10–15</td>
</tr>
<tr>
<td>U2AF1</td>
<td>21q22</td>
<td>exons 2–7</td>
<td>rare, rare, rare 5–15</td>
</tr>
</tbody>
</table>

PV, polycythemia vera; ET, essential thrombocytopenia; PMF, primary myelofibrosis.

© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
Evolution of JAK2 V617F mutated ET to PV is sometimes observed, correlating with an increase in JAK2 V617F burden. Similarly, the evolution towards myelofibrosis is accompanied by, or possibly due to, an increase in JAK2 V617F burden. Therefore, at MPN diagnosis measurement of the allele burden may help to discriminate between different MPN phenotypes: when an allele burden is greater than 50%, the likelihood exists of a masked PV (possibly due to iron deficiency) or myelofibrotic evolution. The JAK2 V617F allelic burden may also have prognostic significance: PV patients with a high JAK2 V617F burden are more likely to evolve towards myelofibrosis, to have a thrombotic event, and to present with higher haemoglobin levels, higher white blood cell (WBC) counts, lower platelet counts and splenomegaly (21). For ET patients, JAK2 V617F levels equate with WBC counts but inversely correlate with platelet counts with high allelic burdens also appearing to predict a higher risk of thrombosis (21). Somewhat conversely, independent studies have shown that PMF patients with a JAK2 V617F mutation but a low burden (~25%) have a poor survival (22). The evolution of the JAK2 V617F mutated clone is also a prognostic indicator as significant elevations have been correlated with a higher risk of fibrotic evolution (23).

Besides characterisation of MPN patients at diagnosis, JAK2 V617F quantitation can be useful to assess the efficacy of therapy. Non-specific cytoreductive treatments such as hydroxycarbamide have been shown to decrease JAK2 V617F burdens in some patients, but with overall limited efficiency (24). The specific JAK2 inhibitors, although more efficient in controlling spleen size or general symptoms, show a modest effect on the reduction of the mutant burden (25). The most efficient drug to date is pegylated interferon-alpha-2a which has been reported to induce molecular remissions with techniques able to detect less than 0.1% JAK2 V617F (26). Allogeneic stem cell transplantation (ASCT) is the only treatment potentially able to cure MPN but there remain considerable procedure-related morbidity and mortality issues. Patients for whom the JAK2 V617F level remains >1% one month post-ASCT may possess a higher risk of relapse than those patients with deeper responses with close monitoring able to guide intervention with donor lymphocyte infusion (27, 28).

A plethora of techniques have been described to quantify JAK2 V617F allelic burdens, based upon sequencing (Sanger or pyrosequencing), allelic discrimination or more commonly, quantitative AS-qPCR. Assay performance may vary in terms of limit of detection and specificity as demonstrated by an international comparison of these techniques (29). Suitable techniques should possess the following attributes: a low limit of detection (at least 1% for diagnosis and at least 0.1% for residual disease monitoring), a close to 100% specificity (no false positive at the minimal detection level), a high reproducibility and should be easily transferable between laboratories. Two major studies comparing JAK2 V617F quantitation techniques have shown the most reliable and sensitive to be AS-qPCR with specificity based on primers (29, 30). One such assay using a specific reverse primer had an excellent detection level and specificity and is recommended by the European LeukemiaNet (30, 31). Selection of a PCR primer that anneals 5’ of the mutation may be beneficial to avoid false negatives caused by the rare, alternative JAK2 exon 14 mutations (32).

### JAK2 exon 12 mutations

Although the JAK2 V617F mutation is present in approximately 97% of PV cases, a minority of patients that fulfil the criteria for PV diagnosis have no evidence of the JAK2 V617F mutation. Scrutiny of these patients revealed the presence of several different mutations in exon 12 of the JAK2 gene (7). Mutations were detected in individuals who presented with erythroid hyperplasia and reduced serum erythropoietin levels without concurrent expansion of the megakaryocytic or granulocytic lineages. Furthermore, endogenous erythroid colonies (EEC) could be grown from patient’s blood samples in the absence of erythropoietin. JAK2 exon 12 mutations were absent in ET and PMF patients (7).

A myriad of JAK2 exon 12 mutations have been reported which can be substitutions, deletions, insertions and duplications, and all occur within a 44 nucleotide region in the JAK2 gene which encompasses amino acids 533–547 at the protein level. The most commonly reported mutations are small in-frame deletions of 3–12 nucleotides with a six nucleotide deletion being the most frequent. Complex mutations are present in one-third of cases with some mutations occurring outside this hotspot region. The N542-E543del is the most common mutation (23–30%), the K537L, E543-D544del and F537-K39delinsL represent 10–14%, and R541-E543delinsK comprise less than 10% of these mutations (33). JAK2 exon 12 mutations are located in a region close to the pseudo-kinase domain which acts as a linker between this domain and the Src homology 2 domain of JAK2. Functional studies have shown that JAK2 exon 12 mutations cause factor independent growth similar to JAK2 V617F that can be blocked by JAK inhibitors with phenotypic differences between the V617F and exon 12 resulting in different signalling activation downstream of JAK2. Clinically, patients with a JAK2 exon 12 mutation present at a younger age with approximately 40% of cases being reported at, or below 50 yr of age. Although predominantly associated with a pure erythroid phenotype with haemoglobin levels and haematocrit higher compared to JAK2 V617F positive cases, there is tri-lineage involvement in a small minority of cases (33).

The WHO diagnostic algorithm for suspected PV indicates screening for JAK2 exon 12 mutations in those individuals.
without the JAK2 V617F (5) making identification increasingly important in the differential diagnosis of PV. As JAK2 exon 12 mutations are often present at low levels, Sanger sequencing is suboptimal therefore requiring alternative methods to comprehensively detect all possible mutations. The initial four JAK2 exon 12 mutations were confirmed by AS-PCR (7) but as the number of mutations reported increased, it became apparent that AS-PCR has limited applicability in the routine diagnostic setting. Subsequently, HRM techniques, based upon the kinetics of DNA strand denaturation, have been evaluated by several groups. HRM is able to detect previously described and unknown mutations; however, sensitivity of these individual assays can vary and is dependent on the mutation detected and template quality (34, 35). Locked nucleic acid (LNA)-clamped fragment analysis exhibits superior sensitivity compared to HRM but is unable to detect substitution mutations and large duplications (36). A fragment analysis-based assay with a 2% limit of detection has been developed which can detect insertions or deletions based on amplicon size (37). These techniques are useful for discriminating between mutated and non-mutated patients with characterisation of specific mutations requiring a more sensitive AS-qPCR approach.

From estimates of mutant allele burden obtained by Sanger sequencing and fragment analysis, patients almost exclusively display low JAK2 exon 12 mutant allele burdens (7, 38) necessitating quantitative assays that possess a high degree of sensitivity for monitoring disease. A sensitivity of 0.01% JAK2 exon 12 mutant alleles has been achieved using AS-qPCR assays for ten mutations that represent 80% of all mutations (39) whereas an alternative, quantitative, bead-based assay has shown a sensitivity of approximately 2.5% and covers 56% of known exon 12 mutations (40). The rarity of patients with JAK2 exon 12 mutations and the variation of the mutant allele burden make selection of an appropriate assay for the diagnostic setting challenging.

**MPL exon 10 mutations**

One year after the discovery of the JAK2 V617F mutation, somatic activating mutations of the myeloproliferative leukaemia virus oncogene (MPL) were identified in patients with JAK2 V617F negative ET and PMF but are absent in PV (8, 41). The MPL gene is located on chromosome 1p34, encodes the thrombopoietin receptor and is a key factor for growth and survival of megakaryocytes. Acquired mutations at codon W515 constitutively activate the thrombopoietin receptor by cytokine-independent activation of the downstream JAK-STAT pathway. MPL 515 somatic mutations are stem cell-derived events that involve both myeloid and lymphoid progenitors. The two most recurrent mutations W515L and W515K are found in approximately 15% of JAK2 V617F-negative MPN, that is 5% of ET and up to 10% of PMF (41). MPL mutations may occur concurrently with the JAK2 V617F mutation (42, 43), and concomitant MPL exon 10 mutations have been reported (42, 44, 45).

Mutations in MPL cluster in exon 10 around amino acid 515 which is located in a stretch of five amino acids (K/RWQFP) found in the cytoplasmic section of the trans-membrane domain. Recurrent pathogenic mutations include the common W515L and W515K and the rare W515A, W515R and W515S mutations. The S505N mutation was first described in familial thrombocythemia but has subsequently been identified as a somatic mutation in ET and PMF (46, 47). Alternative mutations have also reported in rare cases including V501A, S505C, A506T, V507I, G509C, L510P, R514K and R519T, although the pathogenic significance of some of these mutations is not clear (48–50).

Patients with MPL exon 10 mutations have a distinct clinical phenotype tending to have lower haemoglobin levels. ET patients with MPL mutations are also reported to have higher platelet counts, isolated megakaryocytic proliferation and higher serum erythropoietin levels compared to JAK2 V617F positive ET patients. There seems to be no prognostic significance with respect to thrombosis, haemorrhage, myelofibrotic transformation, leukemic transformation or survival. Patients carrying the W515K mutation have higher allelic burdens than those with the W515L allele suggesting a functional difference between these variants (41, 47). The mutant allele burden is often greater than 50% and homozygosity has been described, suggesting bi-allelic mutation or loss of heterozygosity (47, 51). Low-level mutations in the range of 3–15% are usually of the W515L type (45, 47).

Screening for MPL mutations is recommended in cases of suspected ET or PMF with unmutated JAK2 and CALR. Different methods have been applied for detection of MPL mutations of which the two main strategies are specific detection of each known mutation separately or scanning the entire exon 10. The first strategy includes AS-PCR, AS-qPCR, pyrosequencing, deep sequencing, bead-based assay with LNA-probes and amplification refractory mutation system-PCR (43, 47, 52–55). Sensitivities are approximately 5% for all approaches with AS-qPCR achieving a sensitivity of 0.1–0.5%. However, several assays are required to detect all mutations. Recently, a multiplexed AS-PCR assay that detects the four most frequent MPL exon 10 mutations (W515L, W515K, W515A and S505N) with 100% specificity and a sensitivity of 2.5% has been developed (45). This multiplex PCR is performed in a two-tube format with detection achieved by fragment analysis. Alternatively, HRM and melting curve analysis (42, 50) allow the detection of all W515, S505 and unknown exon 10 mutations in one reaction with sensitivities of 2–5%. Quantitation of mutant allele burden can be used for monitoring response to therapy as demonstrated in the post-ASCT setting (56). AS-qPCR is the most sensitive method, but exhibits lower specificity due to frequent non-specific binding of the primers. MPL mutation detection is therefore a helpful tool to

© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
assess clonality in JAK2 V617F-negative MPN and establish a diagnosis. For detection of low-level mutations and quantification of mutant allele burden, highly specific and sensitive AS-qPCR methods are warranted.

**CALR exon 9 mutations**

The application of whole exome sequencing to MPN patients led to the recent discovery of somatic mutations in CALR, the gene encoding calreticulin, a calcium binding chaperone associated with the endoplasmic reticulum (9, 10). MPN-associated CALR mutations are insertions, deletions or insertions and deletions (indels) and occur in exon 9 resulting in a +1 base pair frame-shift of the coding sequence and generation of a translated protein with a novel C-terminus that lacks a retrieval sequence (KDEL) typical of normal CALR and other endoplasmic reticulum resident proteins. CALR exon 9 mutations are predominantly heterozygous with the majority of cases (80–90%) carrying a 52-bp deletion: (CALRdel52/type I: c.1092_1143del: L367 fs*46) or a 5-bp insertion CALRins5/type II: c.1154_1155ins-TTGTG; K385 fs*47). Of the remaining cases, more than 50 different variations have been identified.

Extended screening in large cohorts has confirmed the presence of CALR mutations in 60–80% of patients with ET and PMF that are JAK2 and MPL mutation negative (57–59). CALR mutations are occasionally present in RARS-T (60), rarely observed in PV (61) and very rarely may coexist with the JAK2 V617F or BCR-ABL1 (62, 63).

CALR mutation status may also provide information on the clinical phenotype and prognosis. In retrospective analyses of ET and PMF, CALR-mutated patients were found to present with higher platelet count, lower haemoglobin and improved overall survival when compared to JAK2 mutated, MPL mutated or triple negative patients (9). In ET, CALR-mutated cases are associated with a reduced cumulative incidence of thrombosis, reduced major cardiovascular events and a higher incidence of myelofibrotic transformation versus JAK2-mutated patients (9, 57–59). PMF patients with CALR mutations have a reduced rate of red-cell transfusion dependency with an improved survival as compared to JAK2 mutated patients (64). The high prevalence of type 1 and type 2 CALR mutations in ET and PMF has prompted investigators to assess the impact of mutation type on prognosis and phenotype, with a higher frequency of type 1 CALR mutations noted in PMF compared to ET, an association in PMF of type 2 CALR mutations with higher circulating blast count, leucocyte count and inferior survival compared to type 1, and a potential link between CALR mutation type and megakaryocyte function (65–67). CALR mutations are thought to arise in multipotent progenitors, often as initiating events (9, 10) with mutational load increasing with myelofibrotic transformation (68).

The incidence and specificity of CALR mutations in ET and PMF require analytical methods which can determine CALR mutation status accurately and rapidly to aid the diagnostic workup of MPN. Given the multitude and complexity of CALR exon 9 mutations, methodologies that can accommodate this variability will provide most utility in a diagnostic setting. Whilst initial reports employed PCR of CALR exon 9 followed by fragment analysis or Sanger sequencing to determine CALR mutation status (9, 10), subsequent studies have explored the utility of alternative HRM techniques (69). A comparison of the limits of detection for HRM, next-generation sequencing (NGS), and fragment analysis techniques to detect CALR mutations found a bespoke NGS approach capable of detecting mutations when present at a level of 1.25%, an improvement in sensitivity over HRM and fragment analysis (70). The majority of CALR positive samples tested by NGS had greater than 15% mutant alleles suggesting the more readily deployed fragment analysis may be sufficient for routine molecular diagnosis in the majority of clinical laboratories (70). Further investigation by Sanger sequencing would be required to determine the exact nature of the CALR mutation detected by screening approaches.

The value of quantitative assessment of CALR mutations remains to be fully elucidated, yet preliminary data have shown a reduction in CALR allele burden in patients treated with interferon-alpha therapy and a potential role for monitoring disease burden post-ASCT (71, 72).

**Other MPN-associated mutations**

In addition to the phenotypic driver mutations of JAK2, MPL and CALR, many MPN patients also harbour mutations present in patients with other myeloid malignancies such as MDS and AML. Although not entirely diagnostic of an MPN, mutations in these genes that affect epigenetic regulation, cytokine signalling and mRNA splicing are of increased interest in the biology of MPN but incorporation into a molecular diagnostic algorithm is not currently advocated.

Epigenetics concerns the changes in DNA structure that result in alterations of gene expression with DNA methylation and chromatin remodelling the two main mechanisms of epigenetic regulation. Mutations in genes involved in this process such as TET2, DNMT3A or IDH1 and IDH2 have been described in MPN patients in variable frequencies. Two other genes, EZH2 and ASXL1, which are part of the polycomb repressor complex that regulates chromatin remodelling by methylating histones, are also frequently altered in MPN (Table 1).

The TET2 gene encodes a protein that belongs to a family of methylcytosine dioxygenases that are involved in the DNA demethylation process. TET2 mutations may occur in the entire coding sequence and can be of various types: small deletions, insertions, substitutions leading to stop co-
mutations or substitutions affecting amino acid located in conserved positions that result in a loss of catalytic function (73). Mutations of TET2 can occur in both JAK2 V617F-positive and JAK2 V617F-negative MPN but have minimal prognostic impact. Alterations of DNMT3A have been described over the entire coding sequence of the gene, although most mutations occur in exon 23. DNMT3A mutations are found in less than 10% of chronic phase MPN cases (74). IDH1 and IDH2 genes encode the isocitrate dehydrogenases 1 and 2, respectively. Mutations in these genes, IDH1 (R132) or IDH2 (R140, R172), generate metabolites that prevent histone demethylation and block hematopoietic differentiation. IDH1/2 mutations have been detected at a very low frequency in patients with chronic phase MPN but possibly play a pathogenic role in acute transformation (75). Mutations of EZH2 can occur throughout the entire EZH2 coding sequence resulting in protein truncation or alteration of amino acids essential for the methyltransferase function. EZH2 mutations are detected in a small proportion of PV patients but in a greater number of PMF patients where they appear to be associated with an adverse prognosis (76). The ASXL1 gene encodes one of a three-member family of proteins likely to be involved in the control of chromatin structure. ASXL1 mutations are mainly frame shift or nonsense mutations that primarily affect exon 13, but can also be detected throughout the coding sequence. ASXL1 mutations are uncommon in chronic phase ET and PV but are more prevalent in PMF where they appear to impart a significant prognostic impact (77).

Activating mutations of CBL which encodes a regulator of kinase signalling are rare in the classical MPN with exon 8 and exon 9 mutations occurring most commonly in the MDS/MPN syndromes (78). SH2B3 (LNK) is a negative regulator of hematopoietic cytokine signalling with mutations in the coding gene present rarely in chronic phase MPN (79).

In addition to epigenetic regulators, mutations in genes that encode proteins which participate in the process of splicing immature mRNA have also been described in MPN, of which the most widely studied are SF3B1, SRSF2 and U2AF1. Somatic mutations of SF3B1 were initially detected in MDS patients and are especially prevalent in RARS-t where their presence predicts a favourable prognosis (80). In MPN, SF3B1 mutations are mostly found in PMF where they cluster within exons 12–16 (81). The SRSF2 and U2AF1 genes belong to the family of regulatory factors that can activate or repress mRNA splicing. Alterations in SRSF2 are the most frequent in splicing genes and are mostly found in PMF and MPN evolved to AML (19%). Mutations in SRSF2 confer a poor prognosis and may coexist with other mutations as TET2, RUNX1 or ASXL1. U2AF1 mutations are detected in up to 15% of PMF cases, but are not present in ET or PV patients (82). All these mutations appear to accumulate during progression and indicate and advanced state of the disease.

**Quality assurance of MPN molecular diagnostics**

To ensure continued high performance of molecular diagnostics and clinical utility, external quality assurance (EQA) programmes are vital. These are especially important when sensitivity of the assay is critical or when quantitative results are requested, known to vary significantly due to different methodologies and assay designs. However, even among laboratories using qPCR with the same experimental protocol variation can be substantial. To overcome this variation, different approaches for standardisation of qPCR have been assessed. For quantification of BCR-ABL1 fusion gene expression in response to tyrosine kinase inhibition in chronic myeloid leukaemia patients, results may be aligned to an international scale using a laboratory-specific conversion factor enabling consistent interpretation of individual patient response and comparison of response rates in clinical trials. This approach to establish and maintain a valid conversion factor is however, both expensive and time-consuming and has led to the development of an internationally recognised BCR-ABL1 primary reference panel from which commercially available, secondary standards can be calibrated.

Although EQA for JAK2 V617F detection is available, a program dedicated to assays based on AS-qPCR as a single technology is advantageous as quantitative levels can be directly compared without bias introduced by different technologies. In an attempt to standardise the quantitative measurement of the JAK2 V617F, the European LeukemiaNet and MPN&MPN-EuroNet have evaluated different AS-qPCR assays, including assays in widespread clinical use (30). A series of quality control rounds, involving 12 laboratories from seven countries, were undertaken to evaluate performance and finally recommend a single assay with consistent performance across different qPCR platforms for sensitive and quantitative mutation detection demonstrated. In a further MPN&MPN-EuroNet EQA study involving 24 European laboratories, it was shown that there was relative consistency in quantitation of JAK2 V617F allelic burdens above 1% but for values below this level, variation in the specificity and therefore sensitivity exists and is likely due to the assay employed (83).

Proficiency analysis of MPL mutation detection has also been addressed by the MPN&MPN-EuroNet by quality control rounds utilising serial dilutions of plasmids containing the common exon 10 mutations. Whilst there was comparable specificity, a significant variation in sensitivity was noted and was dependent upon assay used (84). These findings suggest caution when interpreting MPL mutation allele.
Future directions

The ability of NGS technologies, platforms and associated bioinformatics pipelines to simultaneously sequence multiple genes and identify mutations within these genes with high specificity and comparable sensitivity lends itself to the molecular diagnosis of MPN in which a high degree of genomic complexity exists. In recent years, NGS has become more widely available and although these platforms may not currently be suited for the detection and/or quantification of MPN-associated mutations in all diagnostic laboratories, the feasibility and accuracy of these methods have already been established in MPN molecular diagnostics: targeted exome sequencing allows the identification of several mutations that have prognostic significance with identification of these mutations demonstrated to be of clinical value in predicting relapse in the post-ASCT setting (85–87). With improvements in sensitivity, targeted NGS of specific MPN-associated mutations may also afford the detection of residual disease and leukemic transformation (88, 89). Development and implementation of both commercial and in-house NGS-based assays for the detection of MPN-associated mutations will require both inter- and intralaboratory evaluation of ongoing performance with preliminary studies addressing these issues achieving high concordance (90).

Another emerging approach for the detection and quantification of MPN-associated mutations is digital PCR which can achieve absolute quantitation of the target allele without the requirement for standard curve construction or comparison to a reference gene. This is achieved by partition of the template DNA into multiple PCR reactions by either droplet formation or nano-fluidics, resulting in improved sensitivity and precision with minimal requirements for validation and standardisation. Such technical advantages of digital PCR have been validated for detection of the JAK2 V617F (91).

Continual appraisal and adaptation will be required by the MPN community to harness the multitude of molecular diagnostic approaches to maximise the efficiency of detection and quantitation of MPN-associated mutations, which in turn should allow improved clinical outcomes for patients. Whilst the diagnosis of MPN remains multidisciplinary, requiring consideration of clinical features, histo-morphological appearances and other laboratory parameters, molecular diagnostics has become, and will continue to be, an increasingly integral part of this process.

Conflict of interest

SEL, HA, JA, BB, SC, KH, LK, EL, OM, EOL, MJP, NPerret, LP, JS, MFM, NPallisgaard & SH have no conflict of interests to declare. SS is part owner of the MLL Munich Leukemia Laboratory.

References


Molecular diagnostics in MPN


